 |
|
|
|
 |
|
|
|
|
|
|
Department
|
Hematology/Oncology
|
|
Hospital Title
|
Assistant in Medicine
|
|
Academic Title
|
Assistant Professor of Pediatrics
|
|
Phone
|
617-632-4985
|
|
Fax
|
617-632-4850
|
|
Email
|
Kimberly Stegmaier
|
|
Location
|
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA 02115
|
 |
 |
|
|
|
|
|
|
|
Kimberly Stegmaier's laboratory champions the importance of cancer therapy discovery in the academic center. Her group focuses on pediatric and other malignancies not well addressed by industry, such as acute myeloblastic leukemia. Dr. Stegmaier's laboratory applies new chemical genomic approaches to the discovery of small molecule modulators of cancer, compounds that serve as tools in the laboratory to further understanding of oncogenesis and as leads for molecularly informed drug discovery. In order to overcome the limitations to traditional target and phenotype-based screening, Dr. Stegmaier and her colleagues developed a chemical genomic approach to screening, gene expression-based high-throughput screening (GE-HTS), in which a gene expression signature serves as a surrogate for different biological states. The initial proof of principle experiments successfully applied this approach to the identification of inducers of acute myeloblastic leukemia (AML) differentiation. Because the GE-HTS platform is an entirely generic system, it can be applied to a multitude of small molecule library screens.
Cancer discovery efforts in the laboratory are actively focused on the following:
- Identification of differentiation agents for AML and pediatric malignancies
- Modulation of "undruggable" oncoproteins (i.e. transcription factors)
- Identification of the protein target of small molecule hits
The laboratory exploits confirmed hits as tool compounds to explore mechanisms of oncogenesis using a variety of approaches: genomic, RNA interference, pharmacologic, and proteomic. The most ambitious goal is the translation of confirmed hits to clinical trial. Clinical trials for AML and Ewing sarcoma have resulted from this research.
|
|
|
|
|
Kimberly Stegmaier received an MD from Harvard Medical School. She completed her pediatrics internship/residency at Children's Hospital Boston and a pediatric hematology/oncology fellowship at the Children's Hospital Boston/Dana-Farber Cancer Institute where she also served as the Chief Fellow.
Dr. Stegmaier has received an American Society of Hematology Fellow Scholar Award, a Hood Foundation Child Health Research Award, and a Sidney Kimmel Cancer Foundation Award. She is currently a Howard Hughes Medical Institute Physician-Scientist Early Career Award recipient, a Smith Family New Investigator, and a Stand-Up-to-Cancer Innovative Research Grant Awardee. She is also an Associate member of the Broad Institute of Harvard and MIT. Outside of her scientific and clinical endeavors, Dr. Stegmaier has a passion for ballet and has performed professionally with Ballet Theater of Boston and the Cambridge Chamber Ballet.
|
|
|
|
|
- Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nature Genetics 2004; 36:257-63.
- Stegmaier K, Corsello SM, Ross KN, Wong JS, DeAngelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 2005; 106: 2841-2848.
- Stegmaier K, Wong JS, Ross KN, Chow KT, Peck D, Wright WD, Lessnick SL, Kung AL, Golub TR. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in ewing sarcoma. PLoS Medicine 2007; 4(4):e122: 0702-0714.
- Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, Kung AL, Golub TR, Stegmaier K. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A 2008; 105: 9751-9756.
- Corsello SM, Roti G, Ross KN, Chow KT, Galinsky I, DeAngelo DJ, Stone RM, Kung AL, Golub TR, and Stegmaier K. Identification of AML1-ETO Modulators by Chemical Genomics. Blood 2009;113:6193-6205.
- Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC , Ross L, Galinsky I, Davis TN, Silver SJ , Root DE, Stone RM, DeAngelo DJ, Carroll M, Hahn WC, Carr SA, Golub TR, Kung AL, and Stegmaier K. Proteomic and Genetic Approaches Identify Syk as an AML Target. Cancer Cell 2009; 16:281-294
|
|
|
|
|
|
|
|
|
|
|
